Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

GILD – Gilead Sciences, Inc.

Gilead Sciences, Inc.
GILD
$169.73
Name : Gilead Sciences, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $210,522,652,672.00
EPSttm : -3.13
finviz dynamic chart for GILD
Gilead Sciences, Inc.
$169.73
0.67%
$1.14
GILD — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

1.72

Margin Of Safety %

-23

Put/Call OI Ratio

0.96

EPS Next Q Diff

-0.38

EPS Last/This Y

-9.13

EPS This/Next Y

11.1

Price

169.73

Target Price

175.12

Analyst Recom

1.63

Performance Q

22.87

Upside

-165.0%

Beta

0.37

Ticker: GILD



22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-10-13GILD147.880.580.70160509
2026-10-14GILD153.60.591.04163159
2026-10-15GILD157.430.610.37167474
2026-10-16GILD156.190.590.39185605
2026-10-19GILD153.090.580.27178094
2026-10-20GILD156.520.571.62181111
2026-10-21GILD153.590.590.73184818
2026-10-22GILD157.220.600.67186144
2026-10-23GILD156.070.600.61188733
2026-10-26GILD158.710.661.09172033
2026-10-27GILD159.240.6628.16173408
2026-10-28GILD159.230.630.33170818
2026-10-29GILD165.610.630.70173515
2026-10-30GILD170.720.630.52181552
2026-11-02GILD170.380.631.59177963
2026-11-03GILD167.50.659.72181905
2026-11-04GILD174.510.860.96207526
2026-11-05GILD167.60.873.97210840
2026-11-06GILD166.890.952.92221023
2026-11-09GILD169.320.960.79216651
2026-11-10GILD170.880.960.80217794
2026-11-11GILD169.690.960.89218610
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1



22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-10-13GILD147.88-12.915059.4-0.43
2026-10-14GILD153.60-11.315764.1-0.40
2026-10-15GILD157.43-11.316093.5-0.40
2026-10-16GILD156.20-10.915180.2-0.40
2026-10-19GILD153.08-10.915020.6-0.40
2026-10-20GILD153.08-10.915020.6-0.40
2026-10-21GILD156.54-10.915565.0-0.40
2026-10-22GILD157.21-10.915578.3-0.40
2026-10-23GILD156.09-10.915184.4-0.40
2026-10-26GILD158.68-10.815492.0-0.40
2026-10-27GILD159.07-10.715372.4-0.43
2026-10-28GILD159.20-10.715351.7-0.43
2026-10-29GILD165.62-11.715861.5-0.46
2026-10-30GILD170.79-11.715757.9-0.46
2026-11-02GILD170.399.215883.6-0.45
2026-11-03GILD167.50-43.115660.8-0.99
2026-11-04GILD174.45-42.516453.6-0.99
2026-11-05GILD167.62-42.515501.9-0.99
2026-11-06GILD166.87-42.515969.1-0.99
2026-11-09GILD169.38-42.516222.1-0.99
2026-11-10GILD170.88-41.416146.7-0.98
2026-11-11GILD169.73-41.415935.9-0.98
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1



21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-10-13GILD-8.280.151.76
2026-10-14GILD-8.280.151.76
2026-10-15GILD-8.280.151.76
2026-10-16GILD-8.280.151.76
2026-10-19GILD-8.280.121.76
2026-10-20GILD-8.280.121.76
2026-10-21GILD-8.280.121.76
2026-10-22GILD-8.280.121.76
2026-10-23GILD-8.280.121.76
2026-10-26GILD-8.28-0.231.76
2026-10-27GILD-8.28-0.231.64
2026-10-28GILD-8.28-0.231.64
2026-10-29GILD-8.28-0.231.64
2026-10-30GILD-7.85-0.231.64
2026-11-02GILD-7.85-0.131.64
2026-11-03GILD-9.15-0.131.64
2026-11-05GILD-9.15-0.131.64
2026-11-06GILD-9.15-0.131.64
2026-11-09GILD-13.600.461.64
2026-11-10GILD-13.720.461.64
2026-11-11GILD-13.720.461.72
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

2.55

Avg. EPS Est. Current Quarter

1.09

Avg. EPS Est. Next Quarter

2.17

Insider Transactions

-13.72

Institutional Transactions

0.46

Beta

0.37

Average Sales Estimate Current Quarter

8326

Average Sales Estimate Next Quarter

7466

Fair Value

130.22

Quality Score

77

Growth Score

60

Sentiment Score

93

Actual DrawDown %

3.9

Max Drawdown 5-Year %

-26.6

Target Price

175.12

P/E

Forward P/E

16.77

PEG

1.73

P/S

6.78

P/B

16.16

P/Free Cash Flow

15.28

EPS

-3.15

Average EPS Est. Cur. Y​

-0.98

EPS Next Y. (Est.)

10.12

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-12.44

Relative Volume

0.79

Return on Equity vs Sector %

-56

Return on Equity vs Industry %

-64.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.56

EBIT Estimation

15935.9
◆ GILD Healthcare
$169.73
📉
Swing / Pullback
Buy the dip on strong trends
31 /100
WEAK
Trend
6/20
Pullback
10/25
Volume
6/15
Valuation
6/20
TP/AR
1/10
Options
2/10
RSI
62.2
Range 1M
77.3%
Sup Dist
0.7%
🚀
Momentum Growth
Ride accelerating trends
N/A
35 /100
WEAK
Momentum
8/25
Growth
13/30
Estimates
4/20
Inst/Vol
6/15
Options
4/10
EPS Yr
-110.7%
EPS NY
1262.2%
52W%
88.9%
💎
Long-Term Value
Quality companies, undervalued
39 /100
WEAK
🟢 BUY +48% upside
Quality
9/30
Valuation
13/30
Growth
10/25
Stability
4/10
LT Trend
3/5
Upside
+48%
Quality
77
MoS
-23%
Click a card to see score breakdown Full Analysis →
GILD — P/E HistoricalDrug Manufacturers - General
Gilead Sciences, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 17000
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
GILD

Latest News

—
Caricamento notizie per GILD…
stock quote shares GILD – Gilead Sciences, Inc. Stock Price stock today
news today GILD – Gilead Sciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch GILD – Gilead Sciences, Inc. yahoo finance google finance
stock history GILD – Gilead Sciences, Inc. invest stock market
stock prices GILD premarket after hours
ticker GILD fair value insiders trading